Sensus Healthcare, Inc. is a medical device company that develops and markets non-invasive treatments for non-melanoma skin cancer and post-surgical keloid scar prevention. The company utilizes proprietary low-energy X-ray technology known as superficial radiation therapy (SRT) to provide alternatives to surgery for basal cell and squamous cell skin cancers. Its core product portfolio includes the SRT-100, SRT-100+, and SRT-100 Vision systems, which are installed in dermatology clinics and radiation oncology practices. Sensus also offers the Fair Deal Agreement, a service model that provides equipment, radiation oncology oversight, and on-site device operation by radiotherapy technologists in exchange for a share of reimbursement. The company sells consumables such as lead shielding and radiation safety items, and has launched Sensus Link, a cloud-based software solution for workflow and treatment documentation. Sensus Healthcare Financial Services provides financing options for system acquisitions. The company serves markets primarily in the United States and internationally, with devices installed in multiple countries. Sensus Healthcare, Inc. was organized in 2010 and completed its initial public offering in 2016.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage sensushealthcare.com
Sector Healthcare IR page sensushealthcare.com/investors
Tags
superficial radiation therapy, skin cancer treatment, keloid prevention, dermatology equipment, radiotherapy systems, medical imaging, cloud-based software, healthcare financing, clinical services, SRT-100, SRT-100+, SRT-100 Vision, Sensus Medical Devices Ltd., Sensus Healthcare Services LLC, Fair Deal Agreement, Sensus Healthcare Financial Services, Sensus Link, TransDermal Infusion, Sentinel service program
Press page sensushealthcare.com/investors/press-releases

Metrics

Valuation  
Market cap $ 39.568M
Market cap (USD) $ 39.568M
P/E -2.48
PEG —
P/BV 1.12
P/S 2.38
P/OCF -3.48
P/FCF -3.43
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.9%
ROI -29.4%
ROIC -29.5%
Profit margin -28.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 27.482M 41.807M 24.405M 44.532M 27.042M 9.577M 27.263M 26.427M 20.588M 14.811M 10.273M
Net profit -7.719M 6.647M 485K 24.244M 4.119M -6.836M -1.7M -2.023M -3.711M -346.448K -237.267K
Free cash flow 332K -1.107M -2.374M -1.571M -414K -792.725K -2.507M -9.419M -3.344M -1.137M -1.536M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 3.98 6.92 2.36 7.42 7.22 3.86 3.54 7.4 5.16 5.24 —
Price performance 12m -0.42 1.93 -0.68 0.03 0.87 0.09 -0.52 0.43 -0.02 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.1M 4.96M 13.1M 14M 3.78M 12.1M 17.3M 10.6M 19.7M 6.04M
↳ YoY growth +49.6% +60.0% +165.1% +6.6% -73.1% +221.2% +42.6% -38.5% +85.4% -69.4%
↳ 5y CAGR +12.8% +31.4% +28.4% -4.1% +7.1% +9.9%
Lease liabilities (USD) — — 805,000 1.43M 1.12M 174,000 1.02M 783,000 602,000 471,000
Cash and deposits (USD) 5.04M 10.1M 12.5M 8.1M 14.9M 14.5M 25.5M 23.1M 22.1M 22.1M
Intangible assets (USD) 626,509 530,123 433,737 337,351 337,882 146,000 50,000 — — —
Right-of-use assets (USD) — — 0.00 1.4M 1.08M 169,000 996,000 774,000 581,000 452,000
Cash flow detail
Operating cash flow (USD) -851,024 -3.06M -8.56M -2.11M -434,180 -286,000 -1.41M -2.15M -831,000 528,000
Purchases of property, plant and equipment (USD) -285,998 -287,594 -854,834 -400,593 -358,545 -128,000 -159,000 -229,000 -276,000 -196,000
Change in receivables (cash effect) (USD) -1.03M -2.05M -8.17M -1.22M 10.2M — -5.31M 6.65M -9.21M 13.6M
Change in inventories (cash effect) (USD) -323,962 118,925 -661,419 -1.7M -1.43M 2.74M -3.19M -8.58M 268,000 -4.64M
Change in payables (cash effect) (USD) 633,956 1.31M 1.1M -676,564 -2.3M 962,000 799,000 -2.73M 2.02M -1.47M
Share buybacks (cash effect) (USD) — — — — — — -3M -27,000 — -300,000
Interest paid (cash effect) (USD) -23,773 -43,316 -156,685 — -12,456 -2,000 -2,000 — — —
Income taxes paid (cash effect) (USD) — — — — — — -4.57M -1.44M -2.58M -980,000
Share-based compensation (USD) 726,377 405,896 982,624 620,925 386,483 415,000 187,000 328,000 323,000 295,000
Operating cash flow before change in receivables (USD) 176,039 -1.01M -389,332 -891,310 -10.7M — 3.9M -8.79M 8.38M -13.1M
Free cash flow (OCF - PPE - intangibles) (USD) -1.14M -3.34M -9.42M -2.51M -792,725 -414,000 -1.57M -2.37M -1.11M 332,000
Income detail
Research and development expense (USD) 1.82M 5.49M 6.26M 6.42M 4.16M 3.44M 3.46M 3.68M 4.22M 7.78M
↳ 5y CAGR +23.2% +13.5% -8.8% -10.1% -8.1% +13.3%
Provision for credit losses (USD) — 191,391 -13,280 350,086 24,000 78,000 145,000 7,000 123,000 44,000
Credit cost ratio (credit losses / average receivables) (%) — 4.8% 0.1% 2.6% 0.3% 1.0% 1.0% 0.1% 0.8% 0.3%
Reported Mar 10, 2017 Feb 15, 2018 May 14, 2019 Mar 6, 2020 Mar 5, 2021 Mar 25, 2022 Mar 15, 2024 Mar 15, 2024 Mar 5, 2025 Mar 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy

Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities

BOCA RATON, Fla., November 12, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026.

Highlights included:

● Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer.

● Gross profit increased to $3.3 million from $2.7 million in the third quarter of 2025 and gross margin improved to 55% from 39.1% in the prior-year period.

● Shipped 26 systems, including eight carried over from the second quarter of 2026 due to financing approval timing, compared with 16 in the prior-year period.

BOCA RATON, Fla. – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the third quarter of 2026 on Thursday, November 12, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.

Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029291409/en/

Contacts

Investor Relations Contact Leigh Salvo New Street Investor Relations [email protected]

PrevPrevious Page

'); } } function hideCopyNotif() { $('#copy-notif').removeClass('show').removeAttr('style'); setCopyNotif = false; } });

ELEVATING DERMATOLOGICAL CARE

Stay connected with Sensus Healthcare for more news and updates. For inquiries or further information, please contact us.

Speak with Us

IN THE NEWS

Sensus Healthcare Launches Treat Skin Cancer

READ NOW

Commercial Momentum Builds Following CPT Code Implementation

Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing

CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT

Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets

Company Remains Focused on Delivering Strong Second Half Performance

BOCA RATON, Fla. – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.

Highlights included:

  • Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026 quarter, resulting in part from the inability to record the sale of eight units in Q2 due to financing approval timing. This sale will be recognized in Q3.

  • Customer adoption accelerated through expanding engagement with independent practices, larger physician groups, and health systems.

  • Sales pipeline strengthened following CPT code implementation, supported by increasing physician education, inbound customer inquiries and commercial activity.

  • CMS proposed a 26% increase in the hospital-based SRT delivery code, which, if finalized, would further improve provider economics and support expanded adoption of SRT across hospital and health system settings.

  • International commercial activity expanded across key Asia-Pacific markets, including Australia and New Zealand, supporting future growth opportunities.

  • Active website users increased 153% year-over-year.

  • Company remains committed to delivering strong performance during the second half of 2026.

Management Commentary

“While our reported second quarter revenue was impacted by the timing of financing approvals for eight units, our commercial execution remained strong throughout the quarter. Those units have since been sold and related revenue will be recognized in Q3. The delayed financing approval affected the timing of revenue recognition, not customer demand or commercial execution,” said Joseph Sardano, Chairman and Chief Executive Officer.

“Importantly, we are seeing the benefits of the dedicated CPT codes reflected in growing physician engagement, expanding customer interest, and a strengthening sales pipeline. During the quarter, we broadened relationships with larger physician groups, increased utilization under our Fair Deal Agreement program, and advanced our commercial initiatives in both the U.S. and internationally. In addition, we were particularly encouraged by the level of engagement we experienced across key Asia-Pacific markets, including Australia and New Zealand, where growing awareness of SRT is creating attractive long-term opportunities.

“We entered the third quarter with a healthy pipeline, growing customer engagement, and increasing commercial activity across both our domestic and international markets. We remain encouraged by the momentum we are seeing across the business and focused on executing against our five strategic priorities for 2026 – education and training, accelerating customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability,” concluded Sardano.

Second Quarter 2026 Financial Results

Revenues were $2.3 million for the three months ended June 30, 2026, compared to $7.3 million for the three months ended June 30, 2025, a decrease of $5.0 million, or 68.5%. The decrease in revenue was primarily driven by a lower number of units sold (11 in the three months ended June 30, 2026, including Fair Deal Agreements and rentals, compared to 19 in the three months ended June 30, 2025), reflecting no sales in the current period to a historically large customer. In addition, some systems placed during the quarter were under the Fair Deal Agreement program and rental arrangements, for which revenue is recognized over the term of the agreement rather than at the time of shipment.

Cost of sales was $1.5 million for the three months ended June 30, 2026, compared to $4.4 million for the three months ended June 30, 2025, a decrease of $2.9 million, or 65.9%. The decrease in cost of sales was primarily related to the lower number of units sold.

Gross profit was $0.8 million for the three months ended June 30, 2026, compared to $2.9 million for the three months ended June 30, 2025, a decrease of $2.1 million, or 72.4%. Our overall gross profit percentage was 34.8% in the three months ended June 30, 2026, compared to 39.7% in the corresponding period in 2025. The decrease in gross profit and margin was primarily driven by product mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated with new system placements pursuant to the Fair Deal Agreements, which are recognized upfront while related revenue is recognized over the term of the agreement.

General and administrative expense was $1.8 million for the three months ended June 30, 2026, compared to $2.0 million for the three months ended June 30, 2025, a decrease of $0.2 million, or 10.0%. The net decrease in general and administrative expense was primarily due to lower compensation costs, slightly offset by increases in professional fees.

Selling and marketing expense was $1.1 million for the three months ended June 30, 2026, compared to $1.4 million for the three months ended June 30, 2025, a decrease of $0.3 million, or 21.4%. The decrease was primarily driven by a decrease in tradeshow expenses, commission expenses, and clinical research costs.

Research and development expense was $1.1 million for the three months ended June 30, 2026, compared to $1.5 million for the three months ended June 30, 2025, a decrease of $0.4 million, or 26.7%. The decrease was primarily due to a decrease in product development costs related to next-generation systems and reduced headcount.

Other income of $0.1 million and $0.2 million for the three months ended June 30, 2026 and 2025, respectively, relates primarily to interest income.

The tax expense for the second quarter of 2026 includes a $5.7 valuation allowance against net deferred tax assets.

Net loss was $8.7 million, or $0.53 per share, compared with net loss of $1.0 million, or $0.06 per share, for the three months ended June 30, 2025.

Adjusted EBITDA for the second quarter of 2026 was negative $3 million, compared with negative $1.8 million for the second quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.

Cash, restricted cash and cash equivalents were $15.2 million as of June 30, 2026, compared with $18.3 million as of March 31, 2026. The Company had no outstanding borrowings under its revolving line of credit at June 30, 2026. Prepaid inventory was $0.6 million as of June 30, 2026, compared with $2.5 million as of March 31, 2026. Inventories were $18.5 million as of June 30, 2026, compared with $16.5 million as of March 31, 2026.

Conference Call and Webcast

Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions.

Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

Use of Non-GAAP Financial Information

This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management understands that investors and analysts use Adjusted EBITDA, a non-GAAP financial measure, in analyzing the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

| GAAP TO NON-GAAP RECONCILIATION |

| (unaudited) |

| | | | | | | | | |

| | | For the Three Months Ended | | For the Six Months Ended |

| | | June 30, | | June 30, |

| (in thousands) | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net loss, as reported | | $ | (8,749 | ) | | $ | (1,037 | ) | | $ | (11,375 | ) | | $ | (3,609 | ) |

| Add: | | | | | | | | |

| Depreciation | | | 86 | | | | 99 | | | | 182 | | | | 185 | |

| Stock compensation expense | | | 70 | | | | 67 | | | | 140 | | | | 146 | |

| Income tax expense (benefit) | | | 5,686 | | | | (723 | ) | | | 4,079 | | | | (613 | ) |

| Interest income, net | | | (117 | ) | | | (183 | ) | | | (241 | ) | | | (367 | ) |

| Adjusted EBITDA, non GAAP | | $ | (3,024 | ) | | $ | (1,777 | ) | | $ | (7,215 | ) | | $ | (4,258 | ) |

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission.

To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this press release is issued, except as may be required by applicable law.

| CONSOLIDATED STATEMENTS OF OPERATIONS |

| | | For the Three Months Ended | | For the Six Months Ended |

| | | June 30, | | June 30, |

| (in thousands, except share and per share data) | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| | | (unaudited) | | (unaudited) | | (unaudited) | | (unaudited) |

| Revenues | | $ | 2,290 | | | $ | 7,315 | | | $ | 5,684 | | | $ | 15,659 | |

| Cost of sales | | | 1,521 | | | | 4,412 | | | | 3,924 | | | | 8,403 | |

| Gross profit | | | 769 | | | | 2,903 | | | | 1,760 | | | | 7,256 | |

| Operating expenses: | | | | | | | | |

| General and administrative | | | 1,786 | | | | 1,986 | | | | 3,827 | | | | 4,193 | |

| Selling and marketing | | | 1,054 | | | | 1,389 | | | | 2,771 | | | | 3,575 | |

| Research and development | | | 1,109 | | | | 1,471 | | | | 2,699 | | | | 4,077 | |

| Total operating expenses | | | 3,949 | | | | 4,846 | | | | 9,297 | | | | 11,845 | |

| Loss from operations | | | (3,180 | ) | | | (1,943 | ) | | | (7,537 | ) | | | (4,589 | ) |

| Other income: | | | | | | | | |

| Interest income, net | | | 117 | | | | 183 | | | | 241 | | | | 367 | |

| Other income, net | | | 117 | | | | 183 | | | | 241 | | | | 367 | |

| Loss before income tax | | | (3,063 | ) | | | (1,760 | ) | | | (7,296 | ) | | | (4,222 | ) |

| Provision for (benefit from) income taxes | | | 5,686 | | | | (723 | ) | | | 4,079 | | | | (613 | ) |

| Net loss | | $ | (8,749 | ) | | $ | (1,037 | ) | | $ | (11,375 | ) | | $ | (3,609 | ) |

| Net loss per share – basic | | $ | (0.53 | ) | | $ | (0.06 | ) | | $ | (0.69 | ) | | $ | (0.22 | ) |

| diluted | | $ | (0.53 | ) | | $ | (0.06 | ) | | $ | (0.69 | ) | | $ | (0.22 | ) |

| Weighted average number of shares used in computing net loss per share – basic | | | 16,462,059 | | | | 16,320,036 | | | | 16,462,355 | | | | 16,330,891 | |

| diluted | | | 16,462,059 | | | | 16,320,036 | | | | 16,462,355 | | | | 16,330,891 | |

| CONSOLIDATED BALANCE SHEETS |

| | | As of June 30, | | As of December 31, |

| (in thousands, except shares and per share data) | | | 2026 | | | | 2025 | |

| | | (unaudited) | | |

| Assets | | | | |

| Current assets | | | | |

| Cash, restricted cash and cash equivalents | | $ | 15,186 | | | $ | 22,083 | |

| Accounts receivable, net | | | 1,680 | | | | 6,041 | |

| Inventories | | | 18,459 | | | | 14,563 | |

| Prepaid inventory | | | 607 | | | | 1,522 | |

| Other current assets | | | 1,745 | | | | 1,683 | |

| Total current assets | | | 37,677 | | | | 45,892 | |

| Property and equipment, net | | | 2,748 | | | | 1,976 | |

| Deferred tax asset | | | – | | | | 4,079 | |

| Operating lease right-of-use assets, net | | | 329 | | | | 452 | |

| Other noncurrent assets | | | 505 | | | | 640 | |

| Total assets | | $ | 41,259 | | | $ | 53,039 | |

| Liabilities and stockholders’ equity | | | | |

| Current liabilities | | | | |

| Accounts payable and accrued expenses | | $ | 3,167 | | | $ | 3,343 | |

| Product warranties | | | 267 | | | | 275 | |

| Operating lease liabilities, current portion | | | 274 | | | | 262 | |

| Deferred revenue, current portion | | | 619 | | | | 842 | |

| Total current Liabilities | | | 4,327 | | | | 4,722 | |

| Operating lease liabilities, net of current portion | | | 69 | | | | 209 | |

| Deferred revenue, net of current portion | | | – | | | | 10 | |

| Total liabilities | | | 4,396 | | | | 4,941 | |

| Commitments and contingencies | | | | |

| Stockholders’ equity | | | | |

| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | | | – | | | | – | |

| Common stock, $0.01 par value – 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at June 30, 2026; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025 | | | 169 | | | | 169 | |

| Additional paid-in capital | | | 46,230 | | | | 46,090 | |

| Treasury stock, 593,036 shares at cost, at June 30, 2026 and December 31, 2025 | | | (3,876 | ) | | | (3,876 | ) |

| (Accumulated deficit) retained earnings | | | (5,660 | ) | | | 5,715 | |

| Total stockholders’ equity | | | 36,863 | | | | 48,098 | |

| Total liabilities and stockholders’ equity | | $ | 41,259 | | | $ | 53,039 | |

View source version on businesswire.com: https://www.businesswire.com/news/home/20260813917539/en/

Contacts

Investor Relations Contact Leigh Salvo

New Street Investor Relations

[email protected]

PrevPrevious Page

Next PageNext

'); } } function hideCopyNotif() { $('#copy-notif').removeClass('show').removeAttr('style'); setCopyNotif = false; } });

ELEVATING DERMATOLOGICAL CARE

Stay connected with Sensus Healthcare for more news and updates. For inquiries or further information, please contact us.

Speak with Us

IN THE NEWS

Sensus Healthcare Launches Treat Skin Cancer

READ NOW

Prompts

Sensus Healthcare, Inc. (ticker SRTS), listed in United States.

ETFs Holding Sensus Healthcare, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 104,257 $ 335.708K Nov 12, 2026
DFSV 0.00% 73,772 $ 237.546K Nov 12, 2026
DXUV 0.00% 6,495 $ 20.914K Nov 12, 2026
DFAC 0.00% 44,067 $ 141.896K Nov 12, 2026
DCOR 0.00% 11,510 $ 37.062K Nov 12, 2026
AVSC 0.00% 20,030 $ 46.87K Nov 16, 2026